How Do We Know the Stem Cells Are Alive?
Why Stem Cell Viability & Precise Cell Counting Matter for Real Results
Conditions We Treat
-
Osteoarthritis
-
Rheumatoid Arthritis
-
Psoriatic Arthritis
-
Neuropathy
-
Chronic Pain
-
Long COVID
-
Multiple Sclerosis
-
COPD
-
Autoimmune Conditions
These are just a few of the conditions we address with regenerative therapy.
See the Full List of Conditions We Treat
Many patients considering regenerative treatments don’t realize that not all stem cell therapies are the same. One of the biggest distinctions lies in the source of the cells — whether they come from your own body (autologous) or from a healthy donor (allogeneic). This difference matters not just in theory, but in real clinical outcomes.
What Are Autologous Stem Cells?
Autologous stem cells are harvested from your own body — typically from bone marrow or fat tissue. Because they originate from you, there’s no risk of immune rejection. However, especially in older adults, these cells often lack the regenerative strength needed for effective healing. At SCTE, we often meet people who have been told autologous means “natural” or “safer,” when in reality, it often means less effective.FDA Guidelines vs. Global Practice
In the U.S., the FDA allows only autologous cells for therapy, limiting patient options. Outside the U.S., more advanced protocols use umbilical cord-derived mesenchymal stem cells (UC-MSCs). Clinical research supports their safety and efficacy. For example, Galipeau et al. (2020) in Nature Reviews Drug Discovery showed allogeneic UC-MSCs provide powerful immune regulation and tissue repair.The Cost of Aging: Your Stem Cells Decline With You
When you’re young, your stem cells divide rapidly. But by your 60s, one stem cell divides into just 40,000 cells per month — down from 1 billion in youth. That’s a 25,000-fold drop in regenerative power. Studies like Banfi et al. (2021) in Stem Cell Reports confirm older stem cells show signs of senescence and reduced repair capacity, especially in autologous procedures.Invasiveness vs. Simplicity
Autologous procedures require bone marrow extraction or liposuction — both surgical, painful, and requiring anesthesia. Allogeneic umbilical cord stem cells are infused or injected directly — no surgery, no downtime, no harvesting needed.Why SCTE Uses Umbilical Cord Stem Cells Exclusively
- Young, lab-expanded cells from healthy donors
- Viability rates of 85–94% at time of treatment (Mastrolia et al., 2019)
- No invasive harvesting procedures
- Minimal immune rejection — MSCs are immunoprivileged
- Screened for genetic mutations and pathogen-free
“When you age, your stem cells age with you. Using your own stem cells may not give you the best therapeutic results.” — Dr. Yi Song
Autologous vs. Donor Stem Cells: Quick Comparison
| Factor | Autologous (Your Own) | Donor-Derived (UC-MSCs) |
|---|---|---|
| Cell age | Same as your age (40–70+) | From newborn umbilical cord |
| Collection method | Invasive surgery (bone/fat) | Non-invasive, simple infusion |
| Cell division ability | Reduced by 25,000× with age | High — billions in 30 days |
| Immune rejection risk | None | Minimal (MSCs are immunoprivileged) |
| Viability at use | Often lower (50–70%) | 85–94% (lab-tested) |
Scientific References
- Li C, Zhao H, Cheng L, Wang B. Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell & Bioscience. 2021 Nov 2.
- Cyranoski D. Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review. Journal of Translational Medicine. 2019
- Law S, Chaudhuri S. Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges. Am J Stem Cells. 2013
Talk to One Of Our Stem Cell Experts
Curious about how cell count and viability affect your treatment results? Schedule a one-on-one consultation with our clinical team to review your health goals, get transparent cell data, and receive a personalized plan—rooted in science and backed by decades of healing wisdom.